| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 147.36 KB | Adobe PDF |
Orientador(es)
Resumo(s)
The growing interest in the potential benefits of Cannabis sativa L. (CS) and cannabidiol, has boosted the marketing of dietary supplements (DS) and cosmetic products (CP). However, legal compliance and labelling information lack raises concerns about consumer safety [1]. Analyse labelling information on DS and CP containing CS and/or cannabidiol, available online, and review cannabinoid quantification analytical methods (CQAM). A descriptive, cross-sectional study was conducted from August to October 2024 to collect DS and CP from websites (e.g. pharmacies, herbal stores) containing CS and/or cannabidiol, isolated or in mixtures. The labelling information was analysed (uses, ingredients, interactions, adverse reactions). A literature review was conducted in December 2024 using PubMed® to gather studies about CQAM, using the keywords “Chemistry Techniques, Analytical” [Mesh], “Cannabis sativa”, “Cannabinoids”. A total of 60 products (22 DS; 38 CP) were identified. The most common ingredient was seed oil, present in 73% of DS and 59% of CP. The main indications were associated with skin hydration (16 CP), and as a complement in nervous system problems (18 DS). The literature review resulted in 16 studies. Two high-performance liquid chromatography methods were found the best for cannabinoid quantification, demonstrating good linearity, precision and accuracy. Ingredients, such as CS seed oil and cannabidiol, showed inconsistencies with current Portuguese legislation. Collected DS and CP may differ in CS and other contents, highlighting the importance of quality control and regulatory monitoring, using the validated CQAM identified in this study.
Descrição
Palavras-chave
Cannabis sativa L. Cannabidiol Labelling information
Contexto Educativo
Citação
Batalha, A., Regalo, S., Oliveira, A. I., Pinho, C., & Correia, P. (2025). Dietary supplements and cosmetics with cannabis sativa l. And/or cannabidiol: Analysis of labelling information and cannabinoid quantification methods. 13th APLF Annual Conference, TherapeuTic advances in drug safety 16(S1), 68–69. https://journals.sagepub.com/doi/epub/10.1177/20420986251379201
Editora
SAGE Publications
